Enhancement of ADP-Induced Platelet Aggregation by Cholesterol and Its Prevention by Pyridinolcarbamate

Summary

The authors reported a transient decrease in adhesive platelet count and an enhancement of blood coagulability after administration of cholesterol in rabbits. In such circumstances, platelet aggregability to ADP was examined by 2 methods: 1. measurement of intensity of platelet aggregation induced by ADP using the optical density method and 2. determination of minimum concentration of ADP solution to induce platelet aggregation using a light microscope. Three hours after oral administration of 1 g/kg of cholesterol, the intensity of aggregation in 12 rabbits increased to 106.0 ±2.4% (mean ± S. E.) by 10 ìM, 108.5 ±2.6% by 3 ìM and 110.2 ±3.7% of the value before the administration by 1 ìM of ADP. The differences were statistically significant (P <0.05). At that time, platelet in CPRP collected after cholesterol intake were aggregated by eight-times diluted ADP solution compared to that collected before cholesterol administration in 2 rabbits, four-times in 4 and two-times in 3 among 10 cases. Pyridinolcarbamate, which showed preventive effect against appearance of edematous changes in aortic wall induced by cholesterol and/or adrenaline, prevented these phenomena, when it was given 10 mg/kg orally 3 hours prior to cholesterol administration.

• References

• 1 Ardlie N. G, Kiniotjgh R. H, Schwartz C. J. 1966; In vitro thrombosis and platelet aggregation in myocardial infarction. British Medical Journal I: 888.
• 2 Born G. V. R. 1962; Quantitative investigations into aggregation of blood platelets. Journal of Physiology 162: 67.
• 3 Born G. V. R, Hume M. 1967; Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 215: 1027.
• 4 Didisheim P, Sturm R. E, Owen Jr. C. A. 1970 Experiments on thrombosis and its prevention. Sherbrooke Symposium on Blood Coagulation, Sherbrooke, Quebec..
• 5 Fullerton H. W, Davie W. J. A, Anastasopoulos G. 1953; Relationship of alimentary lipemia to blood coagulability. British Medical Journal 02: 250.
• 6 Hellem A. J. 1968. Platelet adhesiveness. In: Series Haematologica. Vol. I, 2, Munksgaard, Copenhagen: 99.
• 7 Henley A. A. 1957; The determination of serum cholesterol. Analyst 82: 286.
• 8 O’Brien J. R. 1962; Platelet aggregation. Part 2. Some results from a new method of study. Journal of Clinical Pathology 15: 452.
• 9 Sano T, Boxer L. A, Yokoyama M. 1970. Platelet sensitivity to aggregation in normal and diseased groups: A method for assessment of platelet aggregability. Thirteenth Annual Meeting of American Society of Hematology; San Juan, Puerto Rico.:
• 10 Sano T, Boxer M. G. J, Boxer L. A, Yokoyama M. 1971; Platelet sensitivity to aggregation in normal and diseased groups — A method for assessment of platelet aggregability. Thrombosis et Diathesis Haemorrhagica 25: 524.
• 11 Sano T, Yokoyama M. 1971; Effect of pyridinolcarbamate on platelet aggregation. The American Journal of the Medical Sciences 262: 205.
• 12 Shimamoto T, Yamazaki H, Inoue M, Fujita T, Sagawa N, Ishioka T, Sunaga T. 1960; Effect of adrenaline and noradrenaline on “silicone-like property” of blood vessels. Proceedings of the Japan Academy 36: 234.
• 13 Shimamoto T. 1963; The relationship of edematous reaction in arteries to atherosclerosis and thrombosis. Journal of Atherosclerosis Research 03: 87.
• 14 Shimamoto T, Maezawa H, Yamazaki H, Atsumi T, Fujita T, Ishioka T, Sunaga T. 1966; a Pyridinolcarbamate, a bradykinin antagonist in veins. American Heart Journal 71: 297.
• 15 Shimamoto T, Maezawa H, Yamazaki H, Ishioka T, Sunaga T, Fujita T. 1966. b Edematous arterial reaction and its relationship to atherosclerosis and thrombosis. In: Bajusz E, Jasmin G. (ed.), Methods in Achievement of Experimental Pathology. Vol. 1 S. Karger; Basel/New York: 337.
• 16 Shimamoto T. 1972. The damage of the repelling function and the active selective permeability of vascular endothelial cells by atherogenic stress and their prevention. Tokyo Conference on Atherogenesis, Thrombogenesis and Pyridinolcarbamate Treatment; Tokyo.:
• 17 Yamakido M, Oishi N, Yokoyama M. 1970; Studies on ADP-induced platelet aggregation in normal and diseased groups. Hawaii Medical Journal 29: 446.
• 18 Yamazaki H, Sano T, Odakura T, Takeuchi K, Shimamoto T. 1970; a Electrocardiographic and hematological changes by exercise test in coronary patients and pyridinolcarbmate pretreatment, a double-blind crossover trial. American Heart Journal 79: 640.
• 19 Yamazaki H, Kobayashi I, Simamoto T. 1970; b Enhancement of ADP-induced platelet aggregation by exercise test in coronary patients and its prevention by pyridinolcarbamate. Thrombosis et Diathesis Haemorrhagica 24: 438.
• 20 Yamazaki H, Odakura T, Takeuchi K, Sano T. 1970; c Adhesive platelet count and blood coagulability in myocardial infarction and cerebral thrombosis. Thrombosis et Diathesis Haemorrhagica 24: 450.
• 21 Yamazaki H, Sano T, Odakura T, Takeuchi K, Matsumura T, Hosaki S, Shimamoto T. 1971; Appearance of thrombogenic tendency induced by adrenaline and its prevention by ß-adrenergic blocking agent, nialamide and pyridinolcarbmate. Thrombosis et Diathesis Haemorrhagica 26: 251.
• 22 Yamazaki H. 1972. Enhancement of ADP-induced platelet aggregation by adrenaline and cholesterol in vivo and its prevention. Tokyo Conference on Atherogenesis, Thrombogenesis and Pyridinolcarbamat Treatment; Tokyo.:
• 23 Zahavi J, Dreyfuss F. 1969; An abnormal pattern of adenosine diphosphate-induced platelet aggregation in acute myocardial infarction. Thrombosis et Diathesis Haemorrhagica 21: 76.
• 24 Zak B. 1957; Simple rapid mierotechnic for serum total cholesterol. American Journal of Clinical Pathology 27: 583.